Halozyme Therapeutics Inc (NAS:HALO)
$ 59.515 -0.095 (-0.16%) Market Cap: 7.57 Bil Enterprise Value: 8.42 Bil PE Ratio: 19.71 PB Ratio: 16.72 GF Score: 88/100

Halozyme Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 06:00PM GMT
Release Date Price: $28.03 (+0.25%)
Ashwin Pai;Morgan Stanley;Managing Director

It's Ashwin Pai here from Morgan Stanley. Thank you for joining us today. It's the fourth day of the 2020 Global Morgan Stanley Healthcare Research Conference. A quick disclaimer on the webcast disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only.

This webcast is not for members of the press. If you're a member of the press, please disconnect and reach out separately.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. For any questions, please reach out to your Morgan Stanley sales representative.

And we're joined today by Halozyme, represented by the CEO, Helen Torley. And so Helen, thank you so much for joining us today. And as we all know the format for this is a moderated fireside chat. So why don't we dive right in?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot